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To determine the acceptance of Implanon so far, the group of women accepting it, insertion
complications and immediate post insertion problems, if any, and report our initial experience with the method.
This was a retrospective review study of all cases of Implanon acceptors between 1 May and
28 February 2007. Demographic and social factors were collated. Insertion and post-insertion complications
were evaluated.
A total of 2,608 clients accepted contraceptive methods out of which 350 clients had Implanon
capsules inserted within the study period (13.4%). One hundred and ninety-one (54.6%) of the acceptors
desired more children, and therefore using it to space pregnancies, 154 (44.0%) would not want more children,
but opted for the temporary long term method, and 5 (1.4%) were uncertain whether to have more children in
the future or not. The mean age and parity of acceptors were 32.4 years and 3.6 respectively. The mean number
of living children to the women was 3.4.All the women were married.
About three-quarters (75.8%) of the women had secondary and tertiary education. Seventy-two (20.6%) of the
women were taking a modern contraceptive method for the first time. The rest 278 (79.4%) had used one or
more methods of contraception, and were only switching over to Implanon sub-dermal implants. The patients
weighed between 40 and 122 kg with an average of 62.4 kg. Post-insertion complications like infection,
expulsion, bruising and induration were not reported. Four women discontinued the method for varying
reasons.
Women are accepting the new method. Over three-quarters of the clients are switching from
other methods to Implanon. The method appears to have good continuation rate and therefore a promising




Progestin contraceptive methods have been found to
be tolerated by many users for the absence of
estrogenic effects. Implants (Norplant) have been
used in Jos for more than 2 decades as long term
hormonal contraceptive methods. They were found
to be effective, safe, reversible, and convenient
method for many clients. Implanon® is a newly
introduced contraceptive implant system into the
country, developed by Organon . It is a single rod,
long acting, reversible subdermal contraceptive
implant system containing the progestin,
etonogestrel. It consists of a non-biodegradable rod
made of ethylene vinyl-acetate holding 68 mg of
etonogestrel, and meant to provide contraception for
3 years. The rod measures 40 mm in length and 2 mm
in diameter . Implanon is inserted in the first 5 days
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of a woman's natural cycle, day 1 being the first day of
her menstrual bleeding .
Etonogestrel is the active metabolite of desogestrel
and has been used in combined oral contraceptives
for many years with established pharmacological
effects . It has been used in combined oral
contraceptive pills with good effect.
Implanon is suitable for a wide range of women
particularly women who want an easy-to-use
contraceptive method to postpone a first pregnancy,
space pregnancies or stop pregnancies using the
reversible long-term contraception on achieving the
desired family size . Implanon may also be useful for
women who are not satisfied with other contraceptive
methods, or in women in whom estrogen is
contraindicated. Women want and desire
contraceptive methods that are effective, safe and
convenient; and do not interfere with sexual life .
Implanon has been successfully used by more than





There were no insertion or removal complications
like infection, expulsion, bruising or induration. Four
women had discontinued the method giving a
continuation of 98.9% within the 10-month period.
Table 1:
Age inYears 19-47 32.4
Parity 0-11 3.6
No. of Living Children 0-8 3.4






Not Stated 10 (2.8)
350 (100.0)
Table 3:
Would Like To Have More Children 191 (54.6)
Would Not Want To Have More Children 154 (44.0)
Not Sure or Undecided 5 (1.4)
350 (100.0)
Users of Implanon constituted about 13% of the
acceptors of contraception within the study period.
This is higher than the 5% documented for Norplant
in the same centre, and falls within the range of less
than 20% of users of contraceptives in Nigeria . The
acceptability of hormonal contraception depends
mainly upon the level of subjective side effects and
the effect on vaginal bleeding among others . The
major advantages of implants are their effectiveness,
convenience, safety, long-term contraceptive
protection that commence within 24 hours of
insertion and return of fertility almost immediately
after removal . The most common side effect is the
disruption of the menstrual cycle . It is also known
that menstrual disturbance also occurs in untreated
women of reproductive age with amenorrhoea
occurring in about 1% of women, infrequent bleeding
in about 8% and frequent and prolonged bleeding in
less that 0.1% .
Parameters of the Women That Accepted
Implanon in Jos University Teaching Hospital
during the Study Period
Parameter Range Means
Literacy Level of the Women Accepting
Implanon
Literacy Level Number (%)
Total
The Women's Desire for More Children in
the Future or Otherwise
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The use of Implanon is supported in any client who
knows what to expect from it in terms of efficacy,
convenience and limitations like irregular menstrual
bleeding. About one-fifth (20.6%) of the women
were taking a contraceptive method for the first time
while four-fifths of them had been on one method of
contraception or the other and were only switching
over to Implanon sub-dermal implants. A little over
50% of the women were using the method for the
limitation of family size.
The socio-demographic characteristics of Implanon
users revealed that the women were young with the
mean age of 32.4 years. They had the mean parity of
3.6, while the mean of the number of living children
to the women was 3.4. These figures are lower than
the 6.0 and 4.4 for Norplant acceptors respectively in
a previous study . About 54.6% had the desire for
more children after the removal of the implants.
Some of the clients were of parity zero, or yet to be
pregnant but needed to postpone pregnancy using
the implant.
Majority (75.8%) of the clients were of tertiary and
secondary education. Non-literate women appear to
be suspicious of new methods and therefore shunned
the method, constituting less than 3% of the
acceptors. The level of formal education among
Norplant users in Zaria, a largely Hausa and Muslim
community where contraceptive use is generally
low, was reportedly lower . All the women were
married and in stable family relationships, and were
mainly urban dwellers within Jos metropolis.
The mean weight of the women was 62.1 kg.
Because of the reported good Pearl index of
Implanon, Implanon insertion was not limited to
only women of 70 kg or below as initially applied for
Norplant implants. Weight did not appear to be a
barrier to offering Implanon in the unit. This is
because in a clinical trial of 130 women of body
weight above 70 kg for 2-3 years, not a single
pregnancy was recorded . The clients were however
counselled about the possibility of a higher chance of
failure compared with those of lower body weight.
Over three quarters of them had a prior positive
history of previous contraceptive use.
As many as 44% of the clients who had completed
their family size chose to use Implanon instead of a
permanent method of contraception. This means that
despite the fact that they had completed their family
size most clients still chose the option of a long-term
method of contraception and not a permanent
method, or female sterilization.
Insertion complications like infection, expulsion,
bruising and induration were not reported. The
acceptors of Implanon were previous users of other
contraceptive methods in addition to new comers to
any form of contraception.




the study period giving a continuation rate of 98.9% in
the 10 months period. The indications for removal
included adverse side effects 2, husband's disapproval
1, and pregnancy before insertion of the implant 1.
In conclusion, women are accepting this new method.
The initial prospect is good for the clients and
providers alike. Three-quarters of the clients switched
from other methods of contraception to Implanon.
The method appears to be a popular and promising
long term sub-dermal contraceptive method amongst
our women. There is the need to begin to think of
supply logistics and sustainability if the method is to
continue to enjoy the patronage of prospective users.
Women of reproductive age wishing to prevent
pregnancy have a right to safe, effective and well-
tolerated method of contraception. This may just be
one of such a method for many clients.
Implanon appears to have a good acceptance rate
among other methods of contraception. This will
therefore entail that the following measures are put in
place.
1. Close monitoring and follow-up of these clients to
determine client satisfaction with the method, side
effects, safety and effectiveness of Implanon among
Nigerian women.
2. Collaborative studies should be conducted across
the country to determine the acceptability,
effectiveness and safety of Implanon among the
different ethnic groups.
3. Structures for sustainability are put in place
supported by legislation and strong government
policy.
4. The establishment of training centres for
counselling; insertion and removal of implants; and
research on implants, in both the public and private
sectors across the country.
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